Safety and Efficacy of the ZoMaxx™ Drug-Eluting Stent System in Coronary Arteries (ZoMaxx™ II)
A Randomized, Controlled Trial to Evaluate the Safety and Efficacy of the ZoMaxx Drug Eluting Coronary Stent System as Compared to the TAXUS™ Express2™ Paclitaxel-Eluting Stent in de Novo Coronary Artery Lesions
Sponsor: Abbott Medical Devices
A PHASE2 clinical study on Coronary Artery Disease and Coronary Disease, this trial is completed. The trial is conducted by Abbott Medical Devices and has accumulated 8 data snapshots since 2005. Cardiovascular trials of this type often inform treatment guidelines for long-term patient management.
Status Flow
Change History
8 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE2
-
Dec 2018 — Jan 2021 [monthly]
Completed PHASE2
▶ Show 3 earlier versions
-
Jun 2018 — Dec 2018 [monthly]
Completed PHASE2
-
Feb 2017 — Jun 2018 [monthly]
Completed PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Completed PHASE2
First recorded
May 2005
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Abbott Medical Devices
For direct contact, visit the study record on ClinicalTrials.gov .